Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gavo-cel in advanced mesothelin-expressing cancer
NCT03907852Phase 2Active, not recruiting
- Sponsor
- TCR2 Therapeutics Inc.
- Start
- Apr 2019
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
A Phase 2 trial of gavocabtagene autoleucel in malignant mesothelioma, cholangiocarcinoma (CCA), ovarian cancer, non-small cell lung cancer (NSCLC), sponsored by TCR2 Therapeutics Inc.. Started Apr 2019; status: active, not recruiting.
02
Drugs
gavocabtagene autoleucel
03
Conditions
malignant mesotheliomacholangiocarcinoma (CCA)ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03907852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907852.